Increased paracellular absorption by bile salts and P-glycoprotein stimulated efflux of otilonium bromide in Caco-2 cells monolayers as a model of intestinal barrier

Journal of Pharmaceutical Sciences

Volumn 97, Issue 9, 2008, Pages 4087-4100

  Catalioto, Rose Marie ^a   Triolo, Antonio ^a   Giuliani, Sandro ^a   Altamura, Maria ^a   Evangelista, Stefano ^a   Maggi, Carlo Alberto ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

Bile salts; Caco 2 cells; Intestinal absorption; Otilonium bromide; P glycoprotein; Paracellular transport; Permeability

Indexed keywords

BILE SALT; GLYCOPROTEIN P; INULIN; OTILONIUM BROMIDE; RHODAMINE 123; VERAPAMIL;

ARTICLE; CELL TRANSPORT; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MONOLAYER CULTURE;

EID: 53549094941     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21240     Document Type: Article

References (47)

1. Evangelista S. 1999. Otilonium bromide: A selective spasmolytic for the gastrointestinal tract. J Int Med Res 27:207-222.
2. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccarato R. 1998. Otilonium bromide in irritable bowel syndrome: A double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 12:1003-1010.
3. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. 2002. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 14:1331-1338.
4. Maggi CA, Manzini S, Meli A. 1983. Octylonium bromide: A smooth muscle relaxant which interferes with calcium ions mobilisation. Arch Intern Pharmacodyn Ther 264:305-323.
5. Maggi CA, Manzini S, Meli A. 1985. Regional selectivity of calcium blockers at intestinal level. Arch Int Pharmacodyn Ther 276:202-221.
6. 2+ channels and secretion in rat chromaffin cells. Eur J Pharmacol 298:199-205.
7. Evangelista S, Giachetti A, Chapelain B, Neliat G, Maggi CA. 1998. Receptor binding profile of otilonium bromide. Pharmacol Res 38:111-118.
8. 2 receptor antagonist actions of otilonium bromide in the circular muscle of guineapig colon. Naunyn Schmiedeberg's Arch Pharmacol 359: 420-427.
9. Strege PR, Evangelista S, Lyford GL, Sarr MG, Farrugia G. 2004. Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol Motil 16:167-173.
10. Lindqvist S, Hernon J, Sharp P, Johns N, Addison S, Watson M, Tighe R, Greer S, Mackay J, Rhodes M, Lewis M, Stebbings W, Speakman C, Evangelista S, Johnson I, Williams M. 2002. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M3 receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol 137:1134-1142.
11. Sutton JA, Kilminster SG, Mould GP. 1997. The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Eur J Clin Pharmacol 52:365-369.
12. Signorini C, Tosoni S, Ballerini R, Chinol M, Mannucci C. 1984. A study of the absorption of otilonium bromide following oral administration in man. Drugs Exp Clin Res 10:273-276.
13. Amenta F, Baroldi P, Ferrante F, Napoleone P, Meli A. 1991. Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract. Arch Int Pharmacodyn Ther 311: 5-19.
14. 14Cotilonium bromide in the rat: Evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos 128:643-647.
15. Dietrich CG, Geier A, Oude Elferink RPJ. 2003. ABC of oral bioavailability: Transporters as gate-keepers in the gut. Gut 52:1788-1795.
16. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43.
17. Pinto M, Leon-Robine S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Assmann-Simon P, Haffen K, Fogh J, Zweibaum A. 1983. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323-330.
18. Rousset M. 1986. The human colon carcinoma cell lines HT-29 and Caco-2: Two in vitro models for study of intestinal differentiation. Biochimie 68: 1035-1040.
19. Hidalgo IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
20. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
21. Lennernas H, Palm K, Fagerholm U, Artursson P. 1996. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int J Pharm 127:103-107.
22. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man: Fact or myth? Pharm Res 14: 763-766.
23. Larger P, Altamura M, Catalioto R-M, Giuliani S, Maggi CA, Valenti C, Triolo A. 2002. Simultaneous LC-MS/MS determination of reference pharmaceuticals as a method for the characterization of the Caco-2 cell monolayer absorption properties. Anal Chem 74:5273-5281.
24. Chattopadhyay A, London E. 1984. Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge. Anal Biochem 139:408-412.
25. Evangelista S. 2004. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 10:3561-3568.
26. Hunter J, Hirst BH, Simmons NL. 1993. Drug absorption limited by P-glycoprotein mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743-749.
27. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. 2003. P-glycoprotein: From genomics to mechanism. Oncogene 22:7468-7485.
28. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. 1996. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br J Pharmacol 118: 1841-1847.
29. Mouly S, Paine MF. 2003. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20:1595-1599.
30. Englund G, Hallberg P, Artursson P, Michaëlsson K, Melhus H. 2004. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2:8.
31. Stephens RH, O'neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. 2001. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-591.
32. Troutman MD, Thakker DR. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20:1200-1209.
33. Stormer E, Perloff MD, Von Moltke LL, Greenblatt DJ. 2001. Methadone inhibits Rhodamine 123 transport in Caco-2 cells. Drug Metab Dispos 29: 954-956.
34. Troutman MD, Thakker DR. 2003. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 20:1192-1199.
35. Ingels FM, Degerme S, Destexhe E, Oth M, Van den Mooter G, Augustijns P. 2002. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int J Pharm 232:183-192.
36. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89:429-442.
37. Ingels FM, Augustijns PF. 2003. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. J Pharm Sci 92: 1545-1558.
38. Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M. 1997. Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: Assessment by confocal laser scanning microscopy. J Pharm Sci 86:779-785.
39. Lanzarotto F, Panarotto B, Sorbara R, Panteghini M, Pagani F, Sosta S, Lanzini A. 1999. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: Evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. Gut 44:552-556.
40. Hanson DS, Duane WC. 1994. Effects of lovastatin and Chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects. J Lipid Res 35:1462-1468.
41. Hasegawa K, Terada S, Kubota K, Itakura H, Imamura H, Ohnishi S, Aoki T, Ijichi M, Saiura A, Makuuchi M. 2003. Effect of apolipoprotein E polymorphism on bile lipid composition and the formation of cholesterol gallstone. Am J Gastroenterol 98: 1605-1609.
42. Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K. 1996. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol 134:1031-1049.
43. Artursson P, Magnusson C. 1990. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci 79:595-600.
44. Thomas LA, Veysey MJ, French G, Hylemon PB, Murphy GM, Dowling RH. 2001. Bile acid metabolism by fresh human colonic contents: A comparison of caecal versus faecal samples. Gut 49:835-842.
45. Alberts DS, Einspahr JG, Earnest DL, Krutzsch MF, Lin P, Hess LM, Heddens DK, Roe DJ, Martinez ME, Salen G, Batta AK. 2003. Fecal bile acid concentrations in a subpopulation of the wheat bran fiber colon polyp trial. Cancer Epidemiol Biomarkers Prev 12:197-200.
46. Williams AJ, Merrick MV, Eastwood MA. 1991. Idiopathic bile acid malabsorption - A review of clinical presentation, diagnosis and response to treatment. Gut 32:1004-1006.
47. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ. 1997. Postinfective diarrhoea and bile acid malabsorption. J R Coll Phys Lond 31:53-56.